|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| MarketWatch: Health Round-up |
|
|
|
|
€ 320,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Juillet 2008 |
Taille du document : |
48 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
ePharmacies: Strategic Implications for the Healthcare Industry
230 pages | Mars 2000 |
Increasingly, the pharmaceutical sector is being influenced by the Internet.Are you in a position to:- Predict future shifts in drug prescribing and purchasing behavior?- Anticipate consolidation in b |
955,00 €
|
| |
| |
The Global Parallel Trade Outlook 2001 - 2006: A Country-by-Country Analysis
188 pages | Septembre 2001 |
Global Parallel Trade Outlook 2001: A country-by-country analysis, a new report by Reuters Business Insight, provides a detailed update on the status of parallel trade in the global marketplace.
1 200,00 €
|
|
| |
| |
Pharmaceutical Pricing Strategies 2000: Entering the new millennium
240 pages | Juin 2000 |
The favorable climate of the pharmaceutical sector has changed radically over the past ten years.
Where once a company's freedom over pricing decisions was almost limitless, external pressure |
955,00 €
|
| |
| |
Pharmaceutical Packaging: UK
90 pages | Avril 2000 |
· Analyse the changes in demand for pharmaceutical packaging in the UK, over the next 5 years
· Understand the main factors affecting demand
· Examine the struct |
1 249,31 €
|
| |
| |
Healthcare In Wales
50 pages | Mai 2000 |
The Welsh Presentation Includes:- The Structure Of The NHS In Wales- Revenue Expenditure On Health Services In Wales- Number Of Hospital Units - Number Of Available Inpatient Beds- Number Of Occupied |
327,00 €
|
| |
| |
The Evolution of DTC marketing across key pharmaceutical markets
152 pages | Mars 2000 |
Pharmaceutical companies mainly market their products through contact between their sales force and heathcare providers.
However, due to the nature of its products, the pharmaceutical industry |
955,00 €
|
| |
| |
Strategic Intelligence: The Top 12 Pharmaceutical Companies
158 pages | Novembre 2001 |
The pressure on the pharmaceutical company R&D has never been greater.
It is estimated that $100 billion worth of products will face patent expiry by 2005.
Of this, $37 billion represe |
1 021,89 €
|
| |
| |
The Pharmaceutical industry in the 21st Century
150 pages | Octobre 1998 |
Does the 21st century herald the beginning of a genomics revolution? Which disease areas will provide the greatest growth potential and why? Which technologies have the greatest potential to max |
795,00 €
|
| |
| |
The Drug Delivery Outlook to 2005
150 pages | Février 1999 |
Strategic overview : defines and values the market covered in the report, provides a macro analysis of the reasons why the drug delivery sector is growing at current rates and predicts how the c |
795,00 €
|
| |
| |
Regulatory Affairs: Paths to Approval
113 pages | Février 1999 |
Area Specific Chapters : The regulatory systems governing clinical trials and drug approvals are examined for the US, Europe, and Australia, Canada and Japan, including analysis of the implicatio |
795,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| MarketWatch: Health Round-up |
|
|
Datamonitor's MarketWatch Health Round-up is a one-stop news shop for time-pressed executives. It provides monthly insight into the key events in the Healthcare industry. The report contains the latest news, analysis and opinion, covering all the month's major issues and events in R&D, regulatory and licensing in the Healthcare industry.
|
|
Pharmaceutical Company Round-up
Page 3
Cancer Update
Page 4 - News Round-up
Page 6 - Opinion: Novartis: positive data point to everolimus potential
Page 7 - Opinion: ImClone/BMS/Merck: Erbitux approval in lung cancer now likely
Page 8 - Opinion: ImClone/BMS/Merck: Erbitux set for breakthrough in Japan
Page 9 - Feature Analysis: Potential lung cancer epidemic looming in Asia
Cardiovascular Update
Page 11 - News Round-up
Central Nervous System Update
Page 13 - News Round-up
Page 15 - Opinion: Lundbeck: Myriad deal is a high risk high reward strategy
IDI Update
Page 16 - News Round-up
Page 18 - Opinion: Type 2 diabetes: major trials show conflicting results
Infectious Diseases Update
Page 19 - News Round-up
Page 21 - Opinion: Novartis AG: Protez snapped up for $400 million
Industry Update
Page 22 - Emergent Biosolutions: acquisition of FluBlok to strengthen infectious diseases portfolio
Page 23 - Daiichi Sankyo: an alternative acquisition strategy
Page 24 - Inhaler devices are still a major hurdle in asthma and COPD treatment
Page 26 - Pharmacovigilance solutions: essential for the future of healthcare
Company Spotlight
Page 28 - Novartis
Biotechnology Update
Page 35 - Biotech News Round-up
Page 37 - Opinion: FDA initiates safety review of TNF blockers
Page 38 - Opinion: Genentech: collaboration prompts speculation over infectious disease interests
Biotechnology Company Spotlight
Page 39 – Genmab A/S
Further Reading
Page 46
Index
Page 47 - Pharma companies
Page 48 - Biotech companies
|
|
|
PPLSEN
|
|
|
|
|
